Emerging Players In Contraceptives Could Reshape A Mature Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The highly competitive, extensively generic contraceptive market has long been characterized by incremental changes in hormone dose, delivery and regimen. But Actavis’ emergence over the past year as a new powerhouse in women’s health is setting the stage for the first new estrogen component in years.
You may also be interested in...
Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Bayer Buys Essure Contraceptive-Maker Conceptus For $1.1 Billion
The acquisition will add a popular nonsurgical, permanent birth control device to Bayer’s line of contraceptive pharmaceuticals and women’s health products.
Barr Seasonale Shows Similar Total Bleeding Days As Standard OCs – FDA
Increased intermenstrual bleeding with Barr’s Seasonale results in the extended-cycle oral contraceptive having a similar number of total bleeding days as standard oral contraceptives, FDA review documents note